KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics,… Read more
Market Cap & Net Worth: KPC Pharmaceuticals Inc (600422)
KPC Pharmaceuticals Inc (SHG:600422) has a market capitalization of $1.25 Billion (CN¥9.20 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #8207 globally and #1510 in its home market, demonstrating a 2.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KPC Pharmaceuticals Inc's stock price CN¥12.15 by its total outstanding shares 756975757 (756.98 Million).
KPC Pharmaceuticals Inc Market Cap History: 2015 to 2026
KPC Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $1.80 Billion to $1.25 Billion (-2.28% CAGR).
KPC Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KPC Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.19x
KPC Pharmaceuticals Inc's market cap is 0.19 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.52x
KPC Pharmaceuticals Inc's market cap is 2.52 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.80 Billion | $4.92 Billion | $420.85 Million | 0.37x | 4.27x |
| 2016 | $1.25 Billion | $5.10 Billion | $407.26 Million | 0.25x | 3.08x |
| 2017 | $863.29 Million | $5.85 Billion | $330.10 Million | 0.15x | 2.62x |
| 2018 | $583.07 Million | $7.10 Billion | $335.54 Million | 0.08x | 1.74x |
| 2019 | $1.02 Billion | $8.12 Billion | $454.31 Million | 0.13x | 2.25x |
| 2020 | $842.56 Million | $7.72 Billion | $456.86 Million | 0.11x | 1.84x |
| 2021 | $1.10 Billion | $8.25 Billion | $507.67 Million | 0.13x | 2.18x |
| 2022 | $1.44 Billion | $8.28 Billion | $383.18 Million | 0.17x | 3.77x |
| 2023 | $2.15 Billion | $8.43 Billion | $540.71 Million | 0.26x | 3.98x |
| 2024 | $1.64 Billion | $8.40 Billion | $648.08 Million | 0.19x | 2.52x |
Competitor Companies of 600422 by Market Capitalization
Companies near KPC Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to KPC Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
KPC Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, KPC Pharmaceuticals Inc's market cap moved from $1.80 Billion to $ 1.25 Billion, with a yearly change of -2.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.25 Billion | -3.26% |
| 2025 | CN¥1.30 Billion | -20.76% |
| 2024 | CN¥1.64 Billion | -24.02% |
| 2023 | CN¥2.15 Billion | +48.99% |
| 2022 | CN¥1.44 Billion | +30.79% |
| 2021 | CN¥1.10 Billion | +31.08% |
| 2020 | CN¥842.56 Million | -17.72% |
| 2019 | CN¥1.02 Billion | +75.62% |
| 2018 | CN¥583.07 Million | -32.46% |
| 2017 | CN¥863.29 Million | -31.16% |
| 2016 | CN¥1.25 Billion | -30.18% |
| 2015 | CN¥1.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of KPC Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.25 Billion USD |
| MoneyControl | $1.25 Billion USD |
| MarketWatch | $1.25 Billion USD |
| marketcap.company | $1.25 Billion USD |
| Reuters | $1.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.